Header Logo

Connection

MARINA KONOPLEVA to Animals

Back to Details
This is a "connection" page, showing publications MARINA KONOPLEVA has written about Animals.
MARINA KONOPLEVA
Connection Strength
1.419
Animals
  1. AML treatment: conventional chemotherapy and emerging novel agents. Trends Pharmacol Sci. 2024 May; 45(5):430-448.
    View in: PubMed
    Score: 0.041
  2. PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity. J Immunother Cancer. 2023 10; 11(10).
    View in: PubMed
    Score: 0.039
  3. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023 01; 29(1):115-126.
    View in: PubMed
    Score: 0.037
  4. Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML. J Immunother Cancer. 2021 07; 9(7).
    View in: PubMed
    Score: 0.033
  5. High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells. Ann Hematol. 2021 Jun; 100(6):1485-1496.
    View in: PubMed
    Score: 0.033
  6. An expert overview of emerging therapies for acute myeloid leukemia: novel small molecules targeting apoptosis, p53, transcriptional regulation and metabolism. Expert Opin Investig Drugs. 2020 Sep; 29(9):973-988.
    View in: PubMed
    Score: 0.032
  7. MDM2 inhibition: an important step forward in cancer therapy. Leukemia. 2020 11; 34(11):2858-2874.
    View in: PubMed
    Score: 0.031
  8. Amino acid metabolism in hematologic malignancies and the era of targeted therapy. Blood. 2019 09 26; 134(13):1014-1023.
    View in: PubMed
    Score: 0.029
  9. Refining statistics clarifies leukaemic stem cell genomics. Br J Haematol. 2019 06; 185(5):1005-1007.
    View in: PubMed
    Score: 0.028
  10. Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype. Clin Adv Hematol Oncol. 2017 Jul; 15(7):554-561.
    View in: PubMed
    Score: 0.025
  11. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia. Expert Opin Ther Targets. 2017 07; 21(7):705-714.
    View in: PubMed
    Score: 0.025
  12. Integration of hypoxic HIF-a signaling in blood cancers. Oncogene. 2017 09 21; 36(38):5331-5340.
    View in: PubMed
    Score: 0.025
  13. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside. Korean J Intern Med. 2017 Mar; 32(2):248-257.
    View in: PubMed
    Score: 0.025
  14. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017 09; 58(9):1-17.
    View in: PubMed
    Score: 0.025
  15. Leukemia Stem Cells Microenvironment. Adv Exp Med Biol. 2017; 1041:19-32.
    View in: PubMed
    Score: 0.025
  16. Frontline treatment of acute myeloid leukemia in adults. Crit Rev Oncol Hematol. 2017 Feb; 110:20-34.
    View in: PubMed
    Score: 0.024
  17. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells. Oncotarget. 2016 Aug 23; 7(34):55083-55097.
    View in: PubMed
    Score: 0.024
  18. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models. Clin Cancer Res. 2016 Apr 01; 22(7):1687-98.
    View in: PubMed
    Score: 0.023
  19. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 2015 Jul 09; 126(2):222-32.
    View in: PubMed
    Score: 0.022
  20. SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. Br J Haematol. 2014 Sep; 166(6):862-74.
    View in: PubMed
    Score: 0.021
  21. Advances in understanding the leukaemia microenvironment. Br J Haematol. 2014 Mar; 164(6):767-78.
    View in: PubMed
    Score: 0.020
  22. Asparaginase unveils glutamine-addicted AML. Blood. 2013 Nov 14; 122(20):3398-400.
    View in: PubMed
    Score: 0.020
  23. Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth. Ann Hematol. 2014 Mar; 93(3):485-492.
    View in: PubMed
    Score: 0.020
  24. TGF-?-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment. PLoS One. 2013; 8(6):e62785.
    View in: PubMed
    Score: 0.019
  25. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol. 2012 Dec; 91(12):1861-70.
    View in: PubMed
    Score: 0.018
  26. Regulation of HIF-1a signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther. 2012 Aug; 13(10):858-70.
    View in: PubMed
    Score: 0.018
  27. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood. 2012 Sep 27; 120(13):2679-89.
    View in: PubMed
    Score: 0.018
  28. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia. 2012 Apr; 26(4):778-87.
    View in: PubMed
    Score: 0.017
  29. Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts. Leukemia. 2012 May; 26(5):883-92.
    View in: PubMed
    Score: 0.017
  30. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One. 2011; 6(8):e23108.
    View in: PubMed
    Score: 0.017
  31. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol. 2011 Feb 10; 29(5):591-9.
    View in: PubMed
    Score: 0.016
  32. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009 Jun 11; 113(24):6215-24.
    View in: PubMed
    Score: 0.014
  33. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 2008 May 01; 68(9):3413-20.
    View in: PubMed
    Score: 0.013
  34. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006 Nov; 10(5):375-88.
    View in: PubMed
    Score: 0.012
  35. Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Mol Cancer Ther. 2006 Feb; 5(2):317-28.
    View in: PubMed
    Score: 0.012
  36. Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells. Cancer Res. 2005 Nov 01; 65(21):9962-70.
    View in: PubMed
    Score: 0.011
  37. Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile. Blood Adv. 2024 May 14; 8(9):2059-2073.
    View in: PubMed
    Score: 0.010
  38. Feasible diet and circadian interventions reduce in?vivo progression of FLT3-ITD-positive acute myeloid leukemia. Cancer Med. 2024 Jan; 13(2):e6949.
    View in: PubMed
    Score: 0.010
  39. Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro. Biochem Pharmacol. 2024 02; 220:115981.
    View in: PubMed
    Score: 0.010
  40. Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL. Leukemia. 2023 10; 37(10):2006-2016.
    View in: PubMed
    Score: 0.010
  41. Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy. Haematologica. 2023 06 01; 108(6):1500-1514.
    View in: PubMed
    Score: 0.010
  42. Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia. Mol Cancer Res. 2023 06 01; 21(6):548-563.
    View in: PubMed
    Score: 0.010
  43. Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia. Leukemia. 2023 06; 37(6):1194-1203.
    View in: PubMed
    Score: 0.009
  44. Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia. Blood. 2023 03 30; 141(13):1610-1625.
    View in: PubMed
    Score: 0.009
  45. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia. 2002 Sep; 16(9):1713-24.
    View in: PubMed
    Score: 0.009
  46. Role of peroxisome proliferator-activated receptor-gamma in hematologic malignancies. Curr Opin Hematol. 2002 Jul; 9(4):294-302.
    View in: PubMed
    Score: 0.009
  47. Novel mitochondria-targeting compounds selectively kill human leukemia cells. Leukemia. 2022 08; 36(8):2009-2021.
    View in: PubMed
    Score: 0.009
  48. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia. Haematologica. 2022 06 01; 107(6):1311-1322.
    View in: PubMed
    Score: 0.009
  49. Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells. Mol Cancer Ther. 2022 06 01; 21(6):879-889.
    View in: PubMed
    Score: 0.009
  50. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nat Commun. 2022 05 19; 13(1):2801.
    View in: PubMed
    Score: 0.009
  51. Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML. Blood. 2022 05 05; 139(18):2782-2796.
    View in: PubMed
    Score: 0.009
  52. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nat Commun. 2022 04 28; 13(1):2228.
    View in: PubMed
    Score: 0.009
  53. Mechanisms of drug resistance in AML. Cancer Treat Res. 2002; 112:237-62.
    View in: PubMed
    Score: 0.009
  54. DYRK1a mediates BAFF-induced noncanonical NF-?B activation to promote autoimmunity and B-cell leukemogenesis. Blood. 2021 12 09; 138(23):2360-2371.
    View in: PubMed
    Score: 0.009
  55. BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome. Int J Mol Sci. 2021 Sep 30; 22(19).
    View in: PubMed
    Score: 0.009
  56. Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia. Mol Cancer Ther. 2021 10; 20(10):1809-1819.
    View in: PubMed
    Score: 0.008
  57. Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHD. Front Immunol. 2021; 12:631353.
    View in: PubMed
    Score: 0.008
  58. Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. J Exp Med. 2021 05 03; 218(5).
    View in: PubMed
    Score: 0.008
  59. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021 02 22; 11(2):41.
    View in: PubMed
    Score: 0.008
  60. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 2021 02 04; 137(5):624-636.
    View in: PubMed
    Score: 0.008
  61. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 10 21; 11(1):5327.
    View in: PubMed
    Score: 0.008
  62. CD38 in hematopoietic malignancies. Chem Immunol. 2000; 75:189-206.
    View in: PubMed
    Score: 0.008
  63. AMP-activated protein kinase links acetyl-CoA homeostasis to BRD4 recruitment in acute myeloid leukemia. Blood. 2019 12 12; 134(24):2183-2194.
    View in: PubMed
    Score: 0.008
  64. A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies. Leukemia. 2020 06; 34(6):1646-1657.
    View in: PubMed
    Score: 0.008
  65. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019 12; 25(12):1938-1947.
    View in: PubMed
    Score: 0.008
  66. Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia. Blood. 2019 10 10; 134(15):1257-1268.
    View in: PubMed
    Score: 0.007
  67. Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-Time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia. Mol Cancer Ther. 2019 11; 18(11):1937-1946.
    View in: PubMed
    Score: 0.007
  68. Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia. Mol Cancer Ther. 2019 09; 18(9):1615-1627.
    View in: PubMed
    Score: 0.007
  69. Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia. Mol Cancer Ther. 2019 09; 18(9):1587-1592.
    View in: PubMed
    Score: 0.007
  70. Merger of dynamic two-photon and phosphorescence lifetime microscopy reveals dependence of lymphocyte motility on oxygen in solid and hematological tumors. J Immunother Cancer. 2019 03 18; 7(1):78.
    View in: PubMed
    Score: 0.007
  71. BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment. J Clin Invest. 2019 05 01; 129(5):1878-1894.
    View in: PubMed
    Score: 0.007
  72. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 2019 01 15; 9(2):4.
    View in: PubMed
    Score: 0.007
  73. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019 02; 51(2):296-307.
    View in: PubMed
    Score: 0.007
  74. Apoptosis. Molecules and mechanisms. Adv Exp Med Biol. 1999; 457:217-36.
    View in: PubMed
    Score: 0.007
  75. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018 07; 24(7):1036-1046.
    View in: PubMed
    Score: 0.007
  76. Disruption of Wnt/?-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res. 2018 05 15; 24(10):2417-2429.
    View in: PubMed
    Score: 0.007
  77. Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell. 2017 Dec 11; 32(6):748-760.e6.
    View in: PubMed
    Score: 0.007
  78. Pretreatment with Antiviral Preparation Kagocel Normalizes the Content of Bone Marrow Multipotent Stromal Cells and TNFa in Blood Serum of CBA Mice Disturbed by Administration of S. typhimurium Antigen Complex In Vivo and Maintains High Concentration of IL-10 and Th1 Cytokines. Bull Exp Biol Med. 2017 Oct; 163(6):761-765.
    View in: PubMed
    Score: 0.006
  79. High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. Haematologica. 2017 09; 102(9):1537-1548.
    View in: PubMed
    Score: 0.006
  80. mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL. Mol Cancer Ther. 2017 09; 16(9):1942-1953.
    View in: PubMed
    Score: 0.006
  81. Metabolic interrogation as a tool to optimize chemotherapeutic regimens. Oncotarget. 2017 Mar 14; 8(11):18154-18165.
    View in: PubMed
    Score: 0.006
  82. PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. Sci Rep. 2017 02 21; 7:43013.
    View in: PubMed
    Score: 0.006
  83. Metabolic gatekeeper function of B-lymphoid transcription factors. Nature. 2017 02 23; 542(7642):479-483.
    View in: PubMed
    Score: 0.006
  84. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia. Clin Cancer Res. 2017 07 01; 23(13):3385-3395.
    View in: PubMed
    Score: 0.006
  85. [The effect of the murine stromal cell line MS-5 on the proliferation and apoptosis of human erythromyeloid leukemic cell line K562]. Vopr Onkol. 1997; 43(3):304-8.
    View in: PubMed
    Score: 0.006
  86. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov. 2017 02; 7(2):156-164.
    View in: PubMed
    Score: 0.006
  87. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun. 2016 11 08; 7:13331.
    View in: PubMed
    Score: 0.006
  88. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med. 2016 09 07; 8(355):355ra117.
    View in: PubMed
    Score: 0.006
  89. Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia. Br J Haematol. 2016 08; 174(3):425-36.
    View in: PubMed
    Score: 0.006
  90. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
    View in: PubMed
    Score: 0.006
  91. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal. 2016 Feb 16; 9(415):ra17.
    View in: PubMed
    Score: 0.006
  92. The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations. Cancer Res. 2016 Mar 15; 76(6):1528-37.
    View in: PubMed
    Score: 0.006
  93. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Rep. 2015 Dec 29; 13(12):2715-27.
    View in: PubMed
    Score: 0.006
  94. PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice. Blood. 2015 Sep 24; 126(13):1585-94.
    View in: PubMed
    Score: 0.006
  95. Effects of Kagocel? on the Counts of Multipotent Stromal Cells, Expression of Cytokine Genes in Primary Cultures of Bone Marrow Stromal Cells, and Serum Cytokine Concentrations in CBA Mice. Bull Exp Biol Med. 2015 Jun; 159(2):240-4.
    View in: PubMed
    Score: 0.006
  96. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Blood. 2015 Jul 16; 126(3):363-72.
    View in: PubMed
    Score: 0.005
  97. Tyrosine kinase inhibitors induce mesenchymal stem cell-mediated resistance in BCR-ABL+ acute lymphoblastic leukemia. Blood. 2015 May 07; 125(19):2968-73.
    View in: PubMed
    Score: 0.005
  98. mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. Oncotarget. 2015 Feb 10; 6(4):2088-100.
    View in: PubMed
    Score: 0.005
  99. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014 Sep 11; 371(11):1005-15.
    View in: PubMed
    Score: 0.005
  100. FOXP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells. Bone Marrow Transplant. 2014 Jun; 49(6):793-9.
    View in: PubMed
    Score: 0.005
  101. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Clin Cancer Res. 2014 May 01; 20(9):2363-74.
    View in: PubMed
    Score: 0.005
  102. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-?B mediates chemoresistance. Blood. 2014 Apr 24; 123(17):2691-702.
    View in: PubMed
    Score: 0.005
  103. SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. J Clin Invest. 2014 Apr; 124(4):1512-24.
    View in: PubMed
    Score: 0.005
  104. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014 Mar; 4(3):362-75.
    View in: PubMed
    Score: 0.005
  105. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy. 2014 Jan; 16(1):90-100.
    View in: PubMed
    Score: 0.005
  106. BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood. 2013 Oct 17; 122(16):2864-76.
    View in: PubMed
    Score: 0.005
  107. Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment. Blood. 2013 Jul 18; 122(3):357-66.
    View in: PubMed
    Score: 0.005
  108. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest. 2013 Jun; 123(6):2395-407.
    View in: PubMed
    Score: 0.005
  109. The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo. PLoS One. 2013; 8(3):e58426.
    View in: PubMed
    Score: 0.005
  110. Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment. Blood. 2012 May 24; 119(21):4971-80.
    View in: PubMed
    Score: 0.004
  111. The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db/db) mice. J Biol Chem. 2010 Dec 24; 285(52):40581-92.
    View in: PubMed
    Score: 0.004
  112. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy. 2010 Sep; 12(5):615-25.
    View in: PubMed
    Score: 0.004
  113. Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a. Mol Pharmacol. 2010 Aug; 78(2):226-36.
    View in: PubMed
    Score: 0.004
  114. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med. 2010 Feb; 16(2):205-13.
    View in: PubMed
    Score: 0.004
  115. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest. 2010 Jan; 120(1):142-56.
    View in: PubMed
    Score: 0.004
  116. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008 Feb 06; 100(3):184-98.
    View in: PubMed
    Score: 0.003
  117. PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL. Cancer Biol Ther. 2007 Dec; 6(12):1967-77.
    View in: PubMed
    Score: 0.003
  118. Triterpenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma. PLoS One. 2007 Jun 27; 2(6):e559.
    View in: PubMed
    Score: 0.003
  119. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res. 2007 Jun 01; 13(11):3380-7.
    View in: PubMed
    Score: 0.003
  120. Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med. 2007 Jun; 13(6):730-5.
    View in: PubMed
    Score: 0.003
  121. The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling. Cancer Res. 2007 May 01; 67(9):4210-8.
    View in: PubMed
    Score: 0.003
  122. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant. 2007 Jul; 13(7):838-43.
    View in: PubMed
    Score: 0.003
  123. The synthetic triterpenoid, CDDO, suppresses alloreactive T cell responses and reduces murine early acute graft-versus-host disease mortality. Biol Blood Marrow Transplant. 2007 May; 13(5):521-9.
    View in: PubMed
    Score: 0.003
  124. The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and its derivatives elicit human lymphoid cell apoptosis through a novel pathway involving the unregulated mitochondrial permeability transition pore. Cancer Res. 2007 Feb 15; 67(4):1793-802.
    View in: PubMed
    Score: 0.003
  125. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. Cell Cycle. 2006 Dec; 5(23):2778-86.
    View in: PubMed
    Score: 0.003
  126. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle. 2006 Oct; 5(19):2223-9.
    View in: PubMed
    Score: 0.003
  127. Apoptosis effector mechanisms: a requiem performed in different keys. Apoptosis. 2006 Jun; 11(6):889-904.
    View in: PubMed
    Score: 0.003
  128. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res. 2006 Apr 01; 66(7):3737-46.
    View in: PubMed
    Score: 0.003
  129. Correlation between CXCR4 and homing or engraftment of acute myelogenous leukemia. Cancer Res. 2004 Sep 15; 64(18):6832 author reply 6832-3.
    View in: PubMed
    Score: 0.003
  130. Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival. Stem Cells. 2004; 22(2):188-201.
    View in: PubMed
    Score: 0.002
  131. Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res. 2003 Sep 15; 63(18):5926-39.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.